US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
US4844893A
(en)
|
1986-10-07 |
1989-07-04 |
Scripps Clinic And Research Foundation |
EX vivo effector cell activation for target cell killing
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
DK0517895T3
(da)
|
1990-12-14 |
1997-04-07 |
Univ California |
Kimæriske kæder til receptorforbundne signaltransduktionsveje
|
WO1994026290A1
(en)
|
1993-05-07 |
1994-11-24 |
Immunex Corporation |
Cytokine designated 4-1bb ligand and human receptor that binds thereto
|
US5653977A
(en)
|
1993-09-09 |
1997-08-05 |
Uab Research Foundation |
Anti-idiotypic antibody that mimics the GD2 antigen
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
US20020018783A1
(en)
|
1997-03-20 |
2002-02-14 |
Michel Sadelain |
Fusion proteins of a single chain antibody and cd28 and uses thereof
|
GB9725764D0
(en)
|
1997-12-04 |
1998-02-04 |
Isis Innovation |
HLA-E binding
|
CA2318372C
(en)
|
1998-02-02 |
2008-08-19 |
Johns Hopkins University School Of Medicine |
A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
|
WO1999067360A2
(en)
|
1998-06-25 |
1999-12-29 |
Hemosol Inc. |
Media and methods for expansion of erythroid stem cells for the production of hemoglobin
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
EP1171596A1
(en)
|
1999-04-16 |
2002-01-16 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
JP3619853B2
(ja)
|
1999-11-26 |
2005-02-16 |
独立行政法人理化学研究所 |
ナチュラルキラー細胞の増殖方法
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
TW200718784A
(en)
|
2001-08-15 |
2007-05-16 |
Takara Bio Inc |
Method of extended culture for antigen-specific cytotoxic T lumphocytes
|
JP2004538331A
(ja)
|
2001-08-17 |
2004-12-24 |
ロジャー ウィリアムス ホスピタル |
インサイチュ免疫法
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
CA2483343A1
(en)
|
2002-04-22 |
2003-10-30 |
Fred Hutchinson Cancer Research Center |
Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
WO2004027036A2
(en)
|
2002-09-19 |
2004-04-01 |
Johns Hopkins University School Of Medicine |
Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
|
GB0225279D0
(en)
|
2002-10-30 |
2002-12-11 |
Celltech R&D Ltd |
Biological products
|
US9068234B2
(en)
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
EP1639001A1
(en)
|
2003-06-27 |
2006-03-29 |
Dnavec Research Inc. |
Method for transplanting lymphohematopoietic cells into mammal
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
WO2005118788A2
(en)
*
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
CA2572938C
(en)
|
2004-07-10 |
2019-10-15 |
Fox Chase Cancer Center |
Genetically modified human natural killer cell lines
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
GB0426903D0
(en)
|
2004-12-08 |
2005-01-12 |
Alexis Biotech Ltd |
Complexes and methods
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
US20070160578A1
(en)
|
2005-12-14 |
2007-07-12 |
The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services |
Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
|
ES2385754T3
(es)
|
2006-06-22 |
2012-07-31 |
Novo Nordisk A/S |
Receptores heterodiméricos solubles y usos de estos
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constituent expression of costimulatory ligands on indirectly transmitted T lymphocytes
|
WO2009117566A1
(en)
|
2008-03-21 |
2009-09-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Chemokine gene-modified cells for cancer immunotherapy
|
HUE058891T2
(hu)
|
2008-08-26 |
2022-09-28 |
Hope City |
Módszer és készítmények a T-sejtek fokozott tumorellenes effektor mûködésének fokozására
|
CN101684456A
(zh)
*
|
2008-09-28 |
2010-03-31 |
江门罗森生物制药有限公司 |
一种体外培养条件下扩增人nk细胞的方法
|
WO2010071836A1
(en)
|
2008-12-19 |
2010-06-24 |
Inserm |
Il-15 mediated nk and t cell maturation
|
CN102428173B
(zh)
|
2009-03-26 |
2014-07-30 |
细胞维护北欧制药公司 |
Nk细胞的扩增
|
EP3135294B1
(en)
|
2009-08-14 |
2020-06-03 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Use of il-15-il-15 receptor heterodimers to treat lymphopenia
|
US20130058921A1
(en)
|
2009-10-30 |
2013-03-07 |
Frits VAN RHEE |
Use of autologous effector cells and antibodies for treatment of multiple myeloma
|
US20130052158A1
(en)
|
2009-10-30 |
2013-02-28 |
University Of Arkansas For Medical Science |
Use of autologous effector cells for treatment of multiple myeloma
|
CA3040276A1
(en)
|
2009-12-02 |
2011-06-09 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
ES2851601T3
(es)
|
2009-12-29 |
2021-09-08 |
Gamida Cell Ltd |
Métodos para mejorar la proliferación y actividad de los linfocitos citolíticos naturales
|
US9422598B2
(en)
|
2010-06-04 |
2016-08-23 |
Biomerieux |
Method and kit for the prognosis of colorectal cancer
|
KR20210063457A
(ko)
|
2010-07-13 |
2021-06-01 |
안트로제네시스 코포레이션 |
천연 킬러 세포의 생성 방법
|
EP2407531A1
(en)
|
2010-07-16 |
2012-01-18 |
Neste Oil Oyj |
Microorganisms with extended substrate utilization range
|
EP2614151B1
(en)
|
2010-09-08 |
2019-07-24 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Interleukin 15 as selectable marker for gene transfer in lymphocytes
|
DK3012268T3
(en)
|
2010-09-08 |
2018-02-19 |
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus |
Chimeric antigen receptors with an optimized hinge region
|
DK3327040T3
(da)
|
2010-09-21 |
2021-09-20 |
Altor Bioscience Corp |
Multimeriske opløselige il-15-fusionsmolekyler og fremgangsmåder til at fremstille og anvende samme
|
TWI664191B
(zh)
|
2010-11-22 |
2019-07-01 |
天賜製藥公司 |
Nk細胞調節治療及治療血液惡性疾病之方法
|
DK3214091T3
(en)
|
2010-12-09 |
2019-01-07 |
Univ Pennsylvania |
USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
|
US20120321666A1
(en)
|
2011-05-23 |
2012-12-20 |
Cooper Laurence J N |
T cell therapy for b cell lymphoma
|
MX2014003176A
(es)
|
2011-09-16 |
2015-08-05 |
Univ Pennsylvania |
Celulas t diseñadas mediante arn para el tratamiento de cancer.
|
US20140255363A1
(en)
|
2011-09-16 |
2014-09-11 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
CA3037175C
(en)
|
2011-09-23 |
2020-04-07 |
Olivier NEGRE |
Improved gene therapy methods
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
CN103294374A
(zh)
|
2012-02-23 |
2013-09-11 |
中兴通讯股份有限公司 |
一种触摸屏解锁方法及装置
|
CN104750498B
(zh)
|
2012-02-24 |
2018-12-18 |
青岛海信电器股份有限公司 |
一种控制鼠标模块的方法及电子设备
|
DK3578201T3
(da)
|
2012-06-28 |
2023-05-08 |
Univ Of Central Florida Research Foundation Incorporated |
Fremgangsmåder og sammensætninger til naturlige dræberceller
|
WO2014011993A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Epitope spreading associated with car t-cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
CA2918608A1
(en)
|
2012-08-03 |
2014-02-06 |
Icahn School Of Medicine At Mount Sinai |
Biomarker associated with risk of melanoma reoccurrence
|
TW201414837A
(zh)
|
2012-10-01 |
2014-04-16 |
Univ Pennsylvania |
標定基質細胞以治療癌症之組合物和方法
|
WO2014055413A2
(en)
|
2012-10-02 |
2014-04-10 |
Bloodcenter Research Foundation |
A method of providing cellular therapy using modified natural killer cells or t lymphocytes
|
JP6441802B2
(ja)
|
2012-10-02 |
2018-12-19 |
メモリアル スローン ケタリング キャンサー センター |
免疫療法のための組成物および方法
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
US20150329640A1
(en)
|
2012-12-20 |
2015-11-19 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
EP3300745B9
(en)
|
2013-02-15 |
2020-04-15 |
The Regents of the University of California |
Chimeric antigen receptor and methods of use thereof
|
DK2961831T3
(da)
|
2013-02-26 |
2020-09-07 |
Memorial Sloan Kettering Cancer Center |
Sammensætninger og fremgangsmåder til immunterapi
|
CN103113470B
(zh)
|
2013-02-27 |
2015-04-22 |
四川大学 |
靶向人egfr的基因工程化淋巴细胞及其制备方法和用途
|
CN105339498A
(zh)
|
2013-03-07 |
2016-02-17 |
贝勒医学院 |
癌症中靶向cd138
|
EP2968601A1
(en)
|
2013-03-10 |
2016-01-20 |
Baylor College Of Medicine |
Chemotherapy-resistant immune cells
|
EP4098275A1
(en)
|
2013-03-15 |
2022-12-07 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
CN105452287A
(zh)
|
2013-04-17 |
2016-03-30 |
贝勒医学院 |
免疫抑制性TGF-β信号转换器
|
KR102095700B1
(ko)
|
2013-05-14 |
2020-04-01 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
가공된 키메라 항원 수용체 (car) t-세포의 인간 적용
|
EA035475B1
(ru)
|
2013-06-10 |
2020-06-23 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Способы и композиции для снижения иммуносупрессии опухолевыми клетками
|
AU2014337195B2
(en)
|
2013-10-17 |
2018-11-08 |
National University Of Singapore |
Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
WO2015066551A2
(en)
|
2013-10-31 |
2015-05-07 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
JP6433498B2
(ja)
|
2013-11-21 |
2018-12-05 |
ユーシーエル ビジネス ピーエルシー |
細胞
|
SG10201804439PA
(en)
|
2013-12-20 |
2018-06-28 |
Hutchinson Fred Cancer Res |
Tagged chimeric effector molecules and receptors thereof
|
CA2934436A1
(en)
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
JP6560235B2
(ja)
|
2014-01-13 |
2019-08-14 |
シティ・オブ・ホープCity of Hope |
Fcスペーサー領域に変異を有するキメラ抗原受容体(CAR)及びそれらの使用方法
|
CN106414723A
(zh)
|
2014-02-10 |
2017-02-15 |
纳维基因股份有限公司 |
细胞调节纳米组合物及使用方法
|
ES2764471T3
(es)
|
2014-02-14 |
2020-06-03 |
Univ Texas |
Receptores de antígeno quimérico y procedimientos de fabricación
|
ES2857226T3
(es)
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
WO2015154012A1
(en)
|
2014-04-03 |
2015-10-08 |
Memorial Sloan-Kettering Cancer Center |
Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
|
NZ725169A
(en)
|
2014-04-25 |
2018-02-23 |
Bluebird Bio Inc |
Mnd promoter chimeric antigen receptors
|
US10428305B2
(en)
|
2014-05-15 |
2019-10-01 |
National University Of Singapore |
Modified natural killer cells that express IL15 and uses thereof
|
CA2951044C
(en)
|
2014-06-06 |
2023-10-03 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
WO2015193411A1
(en)
|
2014-06-18 |
2015-12-23 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Car-expressing nk-92 cells as cell therapeutic agents
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
ES2913865T3
(es)
|
2014-08-28 |
2022-06-06 |
Bioatla Inc |
Receptores de antígeno quimérico condicionalmente activos para células T modificadas
|
GB201415347D0
(en)
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
US10961506B2
(en)
|
2014-09-04 |
2021-03-30 |
Stemcell Technologies Inc. |
Soluble antibody complexes for T cell or NK cell activation and expansion
|
CN107074969A
(zh)
|
2014-09-09 |
2017-08-18 |
优努姆治疗公司 |
嵌合受体及其在免疫治疗中的应用
|
JP6684782B2
(ja)
|
2014-09-15 |
2020-04-22 |
モルメド エスピーエー |
キメラ抗原受容体
|
EP3193894A1
(en)
|
2014-09-16 |
2017-07-26 |
Fundación Pública Andaluza Progreso Y Salud |
Use of cord blood plasma to treat nk cell-mediated diseases and ifn- mediated diseases
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
CN113151167A
(zh)
|
2014-10-27 |
2021-07-23 |
弗罗里达中央大学研究基金会 |
自然杀伤细胞的方法和组合物
|
SG11201703656PA
(en)
|
2014-11-05 |
2017-06-29 |
Juno Therapeutics Inc |
Methods for transduction and cell processing
|
EP3215534B1
(en)
|
2014-11-05 |
2020-04-15 |
Board of Regents, The University of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
CA2964785A1
(en)
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
EP3018200A1
(en)
|
2014-11-07 |
2016-05-11 |
Fondazione Matilde Tettamanti e Menotti de Machi Onlus |
Improved method for the generation of genetically modified cells
|
AU2015344769B2
(en)
|
2014-11-12 |
2020-07-09 |
Allogene Therapeutics, Inc. |
Inhibitory chimeric antigen receptors
|
IL252295B2
(en)
|
2014-12-19 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
Chimeric antigen receptors and methods of using them
|
US20180008637A1
(en)
|
2014-12-31 |
2018-01-11 |
Anthrogenesis Corporation |
Natural killer cells and uses thereof
|
CN107249604A
(zh)
|
2014-12-31 |
2017-10-13 |
人类起源公司 |
使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
EP3247368A4
(en)
|
2015-01-23 |
2019-01-02 |
Musc Foundation for Research Development |
Cytokine receptor genes and the use thereof to enhance therapy
|
MA41433A
(fr)
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
JP6849600B6
(ja)
|
2015-01-29 |
2021-06-30 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
キメラ抗原受容体、組成物及び方法
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
GB201501936D0
(en)
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
EP3253866A1
(en)
|
2015-02-06 |
2017-12-13 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
CN114891816A
(zh)
|
2015-02-06 |
2022-08-12 |
新加坡国立大学 |
核酸、包含其的工程免疫细胞及其制备方法和用途
|
GB201503742D0
(en)
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
SG11201707182WA
(en)
|
2015-03-05 |
2017-10-30 |
Hutchinson Fred Cancer Res |
Immunomodulatory fusion proteins and uses thereof
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
EP3270936A4
(en)
|
2015-03-17 |
2018-08-08 |
Chimera Bioengineering Inc. |
Smart car devices, de car polypeptides, side cars and uses thereof
|
US20180094280A1
(en)
|
2015-03-20 |
2018-04-05 |
Bluebird Bio, Inc. |
Vector formulations
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
US10744157B2
(en)
|
2015-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
|
JP6879932B2
(ja)
|
2015-04-06 |
2021-06-02 |
サイトイミューン セラピューティクス, インコーポレイテッドCytoimmune Therapeutics, Llc |
神経膠芽腫のためのegfr指向car療法
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
US20180092968A1
(en)
|
2015-04-23 |
2018-04-05 |
The Trustees Of The University Of Pennsylvania |
Compositions to disrupt protein kinase a anchoring and uses thereof
|
GB201507108D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
GB201507111D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
GB201507119D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
GB201507115D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
GB201507104D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
US20190031759A1
(en)
|
2015-04-30 |
2019-01-31 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
US11534460B2
(en)
|
2015-05-11 |
2022-12-27 |
University Health Network |
Method for expansion of double negative regulatory T cells
|
AU2016268863B2
(en)
|
2015-05-28 |
2022-06-23 |
Kite Pharma, Inc. |
Diagnostic methods for T cell therapy
|
CA2986755A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
AU2016271147B2
(en)
|
2015-05-29 |
2022-09-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
WO2016197108A1
(en)
|
2015-06-05 |
2016-12-08 |
Board Of Regents, The University Of Texas System |
Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
|
JP2018517415A
(ja)
|
2015-06-10 |
2018-07-05 |
ナントクエスト インコーポレイテッド |
がんを処置するための改変nk−92細胞
|
JP6556523B2
(ja)
|
2015-06-24 |
2019-08-07 |
株式会社やまびこ |
層状掃気式2サイクル内燃エンジン用のエアクリーナ
|
CA2990177A1
(en)
|
2015-06-25 |
2016-12-29 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars), compositions and methods thereof
|
MX2018000278A
(es)
|
2015-06-29 |
2018-03-08 |
Univ Johns Hopkins |
Terapia de receptores quimericos de puntos de control inmunitarios.
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
EP3328994A4
(en)
|
2015-07-31 |
2019-04-17 |
Memorial Sloan-Kettering Cancer Center |
CD56 TARGETING ANTIGEN BINDING PROTEINS AND USES THEREOF
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
EP3331912B1
(en)
|
2015-08-04 |
2024-05-01 |
Xyphos Biosciences Inc. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
|
AU2016304764C1
(en)
|
2015-08-07 |
2023-06-01 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
CN107922498A
(zh)
|
2015-08-24 |
2018-04-17 |
塞勒克提斯公司 |
具有整合可控功能的嵌合抗原受体
|
EP3138905A1
(en)
|
2015-09-04 |
2017-03-08 |
Miltenyi Biotec GmbH |
Method for natural killer cell expansion
|
WO2017058753A1
(en)
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor, regulatory cells and methods of use
|
US11365391B2
(en)
|
2015-09-28 |
2022-06-21 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
RU2753695C2
(ru)
|
2015-11-04 |
2021-08-19 |
Сол Дж. ПРАЙСМЕН |
Химерные рецепторы антигена, нацеленные на her2
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
WO2017079881A1
(zh)
|
2015-11-09 |
2017-05-18 |
张明杰 |
增强对异常细胞杀伤力的方法和药物组合物
|
JP7184645B2
(ja)
|
2015-12-03 |
2022-12-06 |
ジュノー セラピューティクス インコーポレイテッド |
修飾キメラ受容体ならびに関連する組成物および方法
|
JP6853514B2
(ja)
|
2015-12-27 |
2021-03-31 |
国立大学法人東海国立大学機構 |
炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
|
CA3010236A1
(en)
|
2016-01-20 |
2017-07-27 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
CN109715207B
(zh)
|
2016-03-29 |
2023-03-31 |
南加利福尼亚大学 |
靶向癌症的嵌合抗原受体
|
CN105838677B
(zh)
|
2016-05-20 |
2019-07-02 |
杭州优善生物科技有限公司 |
一种高效扩增冷冻保存nk细胞的方法及其应用
|
EP3468994A1
(en)
|
2016-06-08 |
2019-04-17 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
CN105985931A
(zh)
*
|
2016-06-21 |
2016-10-05 |
黑龙江天晴干细胞股份有限公司 |
一种nk细胞体外扩增组合物及nk细胞扩增方法
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Plc |
Protein-based t-cell receptor knockdown
|
EP3487991B1
(en)
|
2016-07-25 |
2022-09-07 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of producing modified natural killer cells and methods of use
|
KR20190098747A
(ko)
|
2016-12-05 |
2019-08-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료법을 위한 조작된 세포의 제조방법
|
CN108148862B
(zh)
|
2016-12-05 |
2019-03-08 |
上海优卡迪生物医药科技有限公司 |
一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
|
WO2018124766A2
(ko)
|
2016-12-28 |
2018-07-05 |
주식회사 녹십자랩셀 |
키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
|
JP7270253B2
(ja)
|
2017-03-27 |
2023-05-10 |
ナショナル ユニヴァーシティ オブ シンガポール |
ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株
|
MX2019011514A
(es)
|
2017-03-27 |
2020-01-27 |
Nat Univ Singapore |
Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
|
US20230002471A1
(en)
|
2017-03-27 |
2023-01-05 |
National University Of Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
US11648269B2
(en)
|
2017-08-10 |
2023-05-16 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
|
CN109554348A
(zh)
|
2017-09-27 |
2019-04-02 |
亘喜生物科技(上海)有限公司 |
可诱导分泌抗cd47抗体的工程化免疫细胞
|
US20210128615A1
(en)
|
2017-10-18 |
2021-05-06 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
CN107827990B
(zh)
|
2017-10-30 |
2020-07-10 |
河北森朗生物科技有限公司 |
一种多肽、编码其的核酸、其修饰的t淋巴细胞及其应用
|
WO2019127215A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
CN109971712B
(zh)
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
|
SG11202007156QA
(en)
|
2018-02-09 |
2020-08-28 |
Nat Univ Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
JP2021512614A
(ja)
|
2018-02-09 |
2021-05-20 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における接着受容体構築物及びその使用
|
KR20200138741A
(ko)
|
2018-04-02 |
2020-12-10 |
내셔널 유니버시티 오브 싱가포르 |
면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
|
CN112601758A
(zh)
|
2018-08-29 |
2021-04-02 |
新加坡国立大学 |
特异性刺激经基因修饰免疫细胞的存活和扩增的方法
|
CN111088231A
(zh)
|
2018-10-24 |
2020-05-01 |
艾生命序公司 |
Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗
|
EP3999082A4
(en)
|
2019-07-17 |
2022-11-30 |
National University of Singapore |
FUNCTIONAL BINDERS SYNTHESIZED AND SECRETED BY IMMUNE CELLS
|